Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period
References (13)
- et al.
Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex
Int J Antimicrob Agents
(2002) - et al.
Usefulness of various antibiotics against Mycobacterium avium–intracellulare, measured by their mutant prevention concentration
Int J Antimicrob Agents
(2005) - et al.
Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterum avium complex pulmonary disease
Chest
(2009) Nontuberculous mycobacteriosis: the present status of epidemiology and clinical studies
Kekkaku
(1999)- et al.
Initial clarithromycin monotherapy for Mycobacterium avium–intracellulare complex lung disease
Am J Respir Crit Care Med
(1994) - et al.
Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients
Am J Respir Crit Care Med
(1996)
Cited by (39)
Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease
2020, Journal of Infection and ChemotherapyMicrobiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review
2018, ChestCitation Excerpt :In the study by Kobashi and Matsushima,39 the minimal inhibitory concentration was measured in only 48 of 65 patients, of whom three were Clari resistant. In only nine of 45 studies22,36-40,42,54,57 were subspecies of MAC (M intracellulare and/or M avium) determined to be present. Subspecies M chimaera was not identified in any of these therapeutic studies.
The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study
2017, Journal of Infection and ChemotherapyCitation Excerpt :We conducted this survey in accordance with the ministerial ordinance on GPSP regarding data handling, self-monitoring, payment or receipt of money, and release of information. Although the ATS/IDSA statement recommend the option of an intermittent, thrice-weekly regimen for patients with nodular bronchiectatic-type disease, a CAM-based daily regimen has been recommended in Japan [15–18]. Thus, a CAM-based daily regimen was selected for the patients enrolled in this study, since some patients might have fibrocavitary-type disease.